A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis SuppurativaThis study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 to 75
Participation Criteria
Inclusion Criteria:
* Have a diagnosis of HS for at least 12 months.
* Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
* Have an (abscess plus inflammatory nodule) count of at least 5.
* Agree to use topical antiseptics daily.
* Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
Exclusion Criteria:
* Have more than 20 draining fistulae.
* Have had surgical treatment for HS in the last 4 weeks before randomization.
* Have an active skin disease or condition, that could interfere with the assessment of HS.
* Have a current or recent acute, active infection.
* Are immunocompromised.
* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
Study Location
Alberta Dermasurgery Centre
Alberta Dermasurgery CentreEdmonton, Alberta
Canada
Contact Study Team
DermEffects - Probity - PPDS
DermEffects - Probity - PPDSLondon, Ontario
Canada
Contact Study Team
Beacon Dermatology
Beacon DermatologyCalgary, Alberta
Canada
Contact Study Team
Simcoderm Medical & Surgical Dermatology Centre
Simcoderm Medical & Surgical Dermatology CentreBarrie, Ontario
Canada
Contact Study Team
Wiseman Dermatology Research Inc.
Wiseman Dermatology Research Inc.Winnipeg, Manitoba
Canada
Contact Study Team
Center de Recherche St Louis
Center de Recherche St LouisQuebec City, Quebec
Canada
Contact Study Team
Brunswick Dermatology Center
Brunswick Dermatology CenterFredericton, New Brunswick
Canada
Contact Study Team
- Study Sponsored By
- Eli Lilly and Company
- Participants Required
- More Information
- Study ID:
NCT06046729